Welcome to our third annual report where we examine the Canadian health tech investment landscape across public and private markets and provide an overview of key current trends we are seeing. 2024… Read More
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie’s pipeline and R&D capabilities NORTH CHICAGO, ILL… Read More
Collaboration leverages AbbVie’s expertise in oncology and immunology drug development and Neomorph’s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees… Read More
Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease,… Read More
VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, commented on the announcement of a $500 billion private-sector investment into AI… Read More
